Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models.

Chen P, Stone J, Sullivan G, Drisko JA, Chen Q.

Free Radic Biol Med. 2011 Aug 1;51(3):681-7. doi: 10.1016/j.freeradbiomed.2011.05.031.

PMID:
21672627
2.

Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.

Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q.

Free Radic Biol Med. 2011 Jun 1;50(11):1610-9. doi: 10.1016/j.freeradbiomed.2011.03.007.

3.

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9.

PMID:
18301895
4.

A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.

Wang W, Adachi M, Zhang R, Zhou J, Zhu D.

Pancreas. 2009 May;38(4):e114-23. doi: 10.1097/MPA.0b013e3181a0b6f2.

PMID:
19342982
5.

High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.

Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q.

Sci Transl Med. 2014 Feb 5;6(222):222ra18. doi: 10.1126/scitranslmed.3007154.

6.

Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2009 Mar 15;69(6):2425-34. doi: 10.1158/0008-5472.CAN-08-2436.

7.

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.

Bigioni M, Benzo A, Irrissuto C, Lopez G, Curatella B, Maggi CA, Manzini S, Crea A, Caroli S, Cubadda F, Binaschi M.

Cancer Chemother Pharmacol. 2008 Sep;62(4):621-9.

PMID:
18038274
8.
9.

Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.

Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.

Biochem Pharmacol. 1987 Jan 1;36(1):147-53.

PMID:
3801051
10.

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP.

Clin Cancer Res. 2002 Dec;8(12):3658-68.

11.

Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.

Sreekanth CN, Bava SV, Sreekumar E, Anto RJ.

Oncogene. 2011 Jul 14;30(28):3139-52. doi: 10.1038/onc.2011.23.

PMID:
21317920
12.

Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.

Smith JP, Stock E, Orenberg EK, Yu NY, Kanekal S, Brown DM.

Anticancer Drugs. 1995 Dec;6(6):717-26.

PMID:
8845483
13.

Ascorbic acid decreases the antifungal effect of fluconazole in the treatment of candidiasis.

Wang Y, Jia XM, Jia JH, Li MB, Cao YY, Gao PH, Liao WQ, Cao YB, Jiang YY.

Clin Exp Pharmacol Physiol. 2009 Oct;36(10):e40-6. doi: 10.1111/j.1440-1681.2009.05187.x.

PMID:
19413603
14.

Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects.

Verrax J, Calderon PB.

Free Radic Biol Med. 2009 Jul 1;47(1):32-40. doi: 10.1016/j.freeradbiomed.2009.02.016.

PMID:
19254759
15.

Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D.

Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29.

PMID:
19823076
16.
17.

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3.

PMID:
21085965
18.

Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.

Zheng LM, Li Z, Liu L, Song BL, King I.

Cancer Chemother Pharmacol. 2007 Jun;60(1):45-51.

PMID:
17256135
19.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.

Cancer Res. 2001 Dec 15;61(24):8758-68.

20.

Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.

Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A.

Semin Oncol. 2000 Feb;27(1 Suppl 1):8-13.

PMID:
10697038

Supplemental Content

Support Center